Prodrug Design: Concepts, carrier-linked prodrugs and bioprecursors MCQs With Answer

Introduction

This quiz collection on Prodrug Design: Concepts, Carrier‑Linked Prodrugs and Bioprecursors is tailored for M.Pharm students studying Advanced Medicinal Chemistry (MPC 103T). It provides focused multiple‑choice questions to reinforce core principles: prodrug rationale, promoieties and linkers, activation mechanisms, enzyme involvement, and representative clinical examples. Questions cover carrier‑linked categories (bipartite, mutual, tripartite, macromolecular), common chemical linkages (esters, carbamates, phosphates), and bioprecursor transformations (oxidation, reduction, cyclization). Use this set to test conceptual understanding and application in prodrug design, predict metabolic pathways, and prepare for exams and project work in formulation and drug development.

Q1. Which statement best describes a carrier‑linked prodrug?

  • A compound that is activated by oxidation without any added promoiety
  • A drug covalently attached to a non‑active promoiety that is cleaved to release the active drug
  • A mixture of two drugs administered together to improve efficacy
  • An inactive metabolite formed after hepatic degradation

Correct Answer: A drug covalently attached to a non‑active promoiety that is cleaved to release the active drug

Q2. Which chemical linkage is most commonly used for carrier‑linked prodrugs intended for enzymatic cleavage in vivo?

  • Ether linkage
  • Ester linkage
  • Azo linkage
  • Carbon‑carbon single bond

Correct Answer: Ester linkage

Q3. Which of the following is a phosphate prodrug designed to increase aqueous solubility of the parent drug?

  • Valacyclovir
  • Fosphenytoin
  • Clopidogrel
  • Capecitabine

Correct Answer: Fosphenytoin

Q4. What defines a mutual prodrug?

  • A prodrug formed by reversible binding to plasma proteins
  • A conjugate of two pharmacologically active molecules linked by a cleavable spacer
  • A prodrug activated only by gut flora
  • A macromolecule that slowly releases a drug by hydrolysis

Correct Answer: A conjugate of two pharmacologically active molecules linked by a cleavable spacer

Q5. Capecitabine is preferentially activated in tumor tissue by which enzyme?

  • Carboxylesterase
  • Thymidine phosphorylase
  • Cytochrome P450 3A4
  • Monoamine oxidase

Correct Answer: Thymidine phosphorylase

Q6. Which of the following is a classic example of a bioprecursor prodrug?

  • Enalapril (an ester prodrug of enalaprilat)
  • Clopidogrel (requires metabolic oxidation to form active thiol metabolite)
  • Fosphenytoin (phosphate prodrug of phenytoin)
  • Valacyclovir (amino‑acid ester prodrug of acyclovir)

Correct Answer: Clopidogrel (requires metabolic oxidation to form active thiol metabolite)

Q7. Which prodrug design strategy is most appropriate to improve passive oral absorption of a polar drug?

  • Introduce a charged phosphate group
  • Reduce molecular weight by cleavage
  • Mask polar functional groups with lipophilic promoieties (e.g., esterification)
  • Increase hydrogen bonding capacity

Correct Answer: Mask polar functional groups with lipophilic promoieties (e.g., esterification)

Q8. Which spacer is commonly used as a self‑immolative linker that undergoes 1,6‑elimination to release the drug?

  • Glycolic acid spacer
  • p‑Aminobenzyl (PAB/PABC) spacer
  • Simple alkyl chain
  • Disulfide bridge

Correct Answer: p‑Aminobenzyl (PAB/PABC) spacer

Q9. A primary pharmacokinetic advantage conferred by prodrug design is:

  • Guaranteed lack of side effects
  • Improved stability, solubility or permeability leading to better bioavailability
  • Permanently inactivating the parent drug
  • Eliminating the need for metabolic enzymes

Correct Answer: Improved stability, solubility or permeability leading to better bioavailability

Q10. Which enzyme class is primarily responsible for hydrolysis of ester prodrugs in plasma and tissues?

  • Cytochrome P450 monooxygenases
  • Carboxylesterases and other esterases
  • Transferases (e.g., glucuronosyltransferase)
  • Proteases

Correct Answer: Carboxylesterases and other esterases

Q11. Which of the following is an example of a macromolecular prodrug or targeted prodrug modality?

  • Trastuzumab emtansine (an antibody‑drug conjugate)
  • Valproic acid
  • Amoxicillin
  • Prednisone

Correct Answer: Trastuzumab emtansine (an antibody‑drug conjugate)

Q12. A major challenge in prodrug design is premature cleavage in plasma. Which property primarily contributes to this problem?

  • High chemical stability of the promoiety
  • Excess lipophilicity preventing enzyme access
  • Susceptibility of the linker to ubiquitous plasma esterases
  • Very large molecular size

Correct Answer: Susceptibility of the linker to ubiquitous plasma esterases

Q13. When selecting a promoiety for a carrier‑linked prodrug, which requirement is essential?

  • The promoiety should be permanently attached and non‑metabolizable
  • The promoiety must be pharmacologically active itself
  • The promoiety should be non‑toxic and metabolically removable to release the parent drug
  • The promoiety should form irreversible covalent bonds with the target

Correct Answer: The promoiety should be non‑toxic and metabolically removable to release the parent drug

Q14. Which of the following is NOT a category of carrier‑linked prodrug?

  • Bipartite prodrug
  • Mutual prodrug
  • Bioprecursor
  • Macromolecular prodrug

Correct Answer: Bioprecursor

Q15. Sulfasalazine is designed as a colon‑specific prodrug. Which activation mechanism is primarily involved?

  • Hydrolysis by pancreatic enzymes
  • Reduction of an azo bond by colonic bacterial azoreductases
  • Oxidation by hepatic CYP450 enzymes
  • Spontaneous photochemical cleavage in the gut

Correct Answer: Reduction of an azo bond by colonic bacterial azoreductases

Q16. Which prodrug was designed to cross the blood‑brain barrier and be converted centrally to the active neurotransmitter?

  • Dopamine
  • L‑DOPA (levodopa)
  • Propranolol
  • Metoprolol

Correct Answer: L‑DOPA (levodopa)

Q17. The phosphoramidate “ProTide” approach (masking the phosphate) used to enhance nucleoside drug delivery is exemplified by which antiviral/prodrug?

  • Fosphenytoin
  • Sofosbuvir
  • Enalapril
  • Valacyclovir

Correct Answer: Sofosbuvir

Q18. Activation of many bioprecursors involves cytochrome P450 oxidation. Which drug is activated by P450‑mediated oxidation to form its active metabolite?

  • Propranolol
  • Clopidogrel
  • Furosemide
  • Metformin

Correct Answer: Clopidogrel

Q19. In prodrug nomenclature, what is meant by the term “promoiety”?

  • The active pharmacophore liberated after metabolism
  • The chemically attached non‑active group designed to modify properties of the parent drug
  • A transporter protein that carries the drug across membranes
  • An enzyme that metabolizes the prodrug

Correct Answer: The chemically attached non‑active group designed to modify properties of the parent drug

Q20. When selecting a cleavable linker for a carrier‑linked prodrug intended for site‑specific release, which factor(s) are most critical?

  • Ease of synthesis only
  • Rate of cleavage under physiological conditions and enzyme specificity at target site
  • Color and odor of the linker
  • Inability to be hydrolyzed in any biological fluid

Correct Answer: Rate of cleavage under physiological conditions and enzyme specificity at target site

Leave a Comment